Retention in care of HIV‐infected pregnant and lactating women starting ART under Option B+ in rural Mozambique
Authors:
- Jara Llenas‐GarcíaJLJara Llenas‐García
- Philip Wikman‐JorgensenPWPhilip Wikman‐Jorgensen
- SolidarMed and IeDEA‐Southern AfricaSASolidarMed and IeDEA‐Southern Africa
- 14 June 2016
- journal article
- research article
- Published by Wiley in Tropical Medicine & International Health
- Vol. 21 (8) , 1003-1012
Abstract
Objective: In 2013, Mozambique adopted Option B+, universal lifelong antiretroviral therapy (ART) for all pregnant and lactating women, as national strategy for prevention of mother‐to‐child transmission of HIV. We analysed retention in care of pregnant and lactating women starting Option B+ in rural northern Mozambique.Methods: We compared ART outcomes in pregnant (‘B+ pregnant’), lactating (‘B+ lactating’) and non‐pregnant non‐lactating women of childbearing age starting ART according to clinical and/or immunological criteria (‘own health’) between July 2013 and June 2014. Lost to follow‐up was defined as no contact >180 days after the last visit. Multivariable competing risk models were adjusted for type of facility (type 1 vs. peripheral type 2 health centre), age, WHO stage and time from HIV diagnosis to ART.Results: Over 333 person‐years of follow‐up (243 ‘B+ pregnant’, 65'B+ lactating’ and 317 ‘own health’ women), 3.7% of women died and 48.5% were lost to follow‐up. ‘B+ pregnant’ and ‘B+ lactating’ women were more likely to be lost in the first year (57% vs. 56.9% vs. 31.6%; P < 0.001) and to have no follow‐up after the first visit (42.4% vs. 29.2% vs. 16.4%; P < 0.001) than ‘own health’ women. In adjusted analyses, risk of being lost to follow‐up was higher in ‘B+ pregnant’ (adjusted subhazard ratio [asHR]: 2.77; 95% CI: 2.18–3.50; P < 0.001) and ‘B+ lactating’ (asHR: 1.94; 95% CI: 1.37–2.74; P < 0.001). Type 2 health centre was the only additional significant risk factor for loss to follow‐up.Conclusions: Retention among PLW starting option B+ ART was poor and mainly driven by early losses. The success of Option B+ for prevention of mother‐to‐child transmission of HIV in rural settings with weak health systems will depend on specific improvements in counselling and retention measures, especially at the beginning of treatment.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (5U01‐AI069924‐05)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (3233B_150934)
This publication has 33 references indexed in Scilit:
- Initiation of Antiretroviral Therapy in Early Asymptomatic HIV InfectionNew England Journal of Medicine, 2015
- Improved Retention of Patients Starting Antiretroviral Treatment in Karonga District, Northern Malawi, 2005–2012JAIDS Journal of Acquired Immune Deficiency Syndromes, 2014
- Health Outcomes and Cost Impact of the New WHO 2013 Guidelines on Prevention of Mother-to-Child Transmission of HIV in ZambiaPLOS ONE, 2014
- The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIVBulletin of the World Health Organization, 2014
- The costs and benefits of Option B+ for the prevention of mother-to-child transmission of HIVAIDS, 2014
- Is Option B+ the best choice?The Lancet, 2013
- Cost-Effectiveness Analysis of Option B+ for HIV Prevention and Treatment of Mothers and Children in MalawiPLOS ONE, 2013
- Cost-effectiveness of World Health Organization 2010 Guidelines for Prevention of Mother-to-Child HIV Transmission in ZimbabweClinical Infectious Diseases, 2012
- Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approachThe Lancet, 2011
- Antiretroviral Regimens in Pregnancy and Breast-Feeding in BotswanaNew England Journal of Medicine, 2010